DIRS.INFO The most relevant business & tech news

☆ Behind the Scenes of the Most Spectacular Show On TV
▼ + stars: | 2023-12-02 | by ( Jody Rosen | ) www.nytimes.com time to read: +4 min

On the possession that followed the Lions’ touchdown, the Chiefs stalled, punting with 5:07 left. And then drama turned to farce, as Mahomes’s receivers let him down and penalties pushed the Chiefs backward. Mahomes took the snap, rolled left and launched a throw that arced across the line to gain, reaching the fingertips of the receiver Skyy Moore, who couldn’t clasp it. On the air, Tirico said: “The Detroit Lions are right there.” In the truck, Hyland’s pronouncement was less circumspect. One measure of the success of “Sunday Night Football” is how “Sunday Night Football”-ish the competing broadcasts are looking.

Persons: ” Collinsworth, Campbell, Tirico, “, Jawaan Taylor, Skycam, Hyland, Esocoff, ”, Mahomes, Skyy Moore, Chiefs weren’t, Gaudelli, “ There’s, Tom Brady, Peyton, Eli, refigures Organizations: Lions, Chiefs, “, NBC, doleful Chiefs, Detroit Lions, CBS, Fox, Fox Sports, bros, NFL Locations: Detroit

☆ Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
▼ + stars: | 2023-12-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

That includes Novo Nordisk 's Wegovy and diabetes treatment Ozempic as well as Eli Lilly 's diabetes drug Mounjaro. They have all skyrocketed in popularity — and slipped into shortages — over the last year for safely and successfully causing significant weight loss. But before the current weight loss industry gold rush, the path to treating obesity was strewn with failures dating back decades. In its full-year 2019 earnings, Eisai reported that Lorcaserin had sales of $28.1 million in the U.S. for the year. Sanofi's rimonabantAn obesity drug called rimonabant from Sanofi and Aventis was withdrawn from all markets in 2008 due to the risk of serious psychiatric problems, including suicide.

Persons: Eli Lilly, drugmakers, lorcaserin, Eisai, Lorcaserin Organizations: Getty, Pfizer, Novo Nordisk, U.S, Drug Administration, FDA, Aventis, Abbott Laboratories Locations: U.S, Sanofi

☆ December's 'best-in-class' stocks include this obesity beneficiary, Wall Street analysts say
▼ + stars: | 2023-12-02 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

An obesity beneficiary and a snack foods company are just a few of the top stocks to buy in December, analysts said this week. Wall Street research firms named a slew of companies that they believe have upside heading into the years end. Obin said the company has a "preponderance" of margin tailwinds for 2024, including "differentiated auto exposure, underappreciated margin expansion opportunities, and best-in-class execution." "We are including BUY-rated EL in our research team's Best-of-Breed Bison initiative, which focuses on long-term best-in-class companies with sustainable competitive moats," analyst Linda Bolton Weiser said earlier this week. Estee Lauder — DA Davidson, buy rating "We are including BUY-rated EL in our research team's Best-of-Breed Bison initiative, which focuses on long-term best-in-class companies with sustainable competitive moats.

Persons: Estee Lauder, Gracell Biotechnologies, Eli Lilly, Andrew Obin, Obin, it's, Nik Modi, Modi, MDLZ, Mondelez, LSEG, Estee Lauder DA Davidson, Linda Bolton Weiser, Bolton Weiser, Gracell, Eli Lilly — Morgan Stanley, Estee Lauder —, Davidson Organizations: CNBC, ITT, Gracell, Bank of America, RBC, ISI, pharma, ITT — Bank of America

☆ Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +23 min

Novo spent at least $25.8 million over the past decade on U.S. medical professionals to promote its two obesity drugs, Wegovy and Saxenda, the analysis found. Jastreboff has also worked on clinical trials of obesity drugs for Eli Lilly, which markets a Wegovy competitor. Some doctors said Novo’s payments exemplify how the flood of industry money can dominate decision-making about care and coverage. Government pharmacy officer Solaru said her agency concluded that the new obesity drugs could be cost-effective by preventing other weight-related diseases and boosting workplace productivity. In January, the personnel office told its health plans they must cover at least one GLP-1 obesity drug for 8 million workers, retirees and family members.

Persons: Lee Kaplan, Kaplan, ”, gastroenterologist, He’s, Novo, Donna Ryan, Ryan, “, ” Kaplan, ” Novo, Robert Lustig, “ I’m, Lustig, They’re, Ania, ” Jastreboff, Jastreboff, Eli Lilly, Lilly’s Zepbound, Lilly, ” Lilly, Novo’s, Ayana, Sanders, Arthur Kellermann, ” Kellermann, mouthpieces, ’ ”, “ I'm, Jamy Ard, Ard, Dele, ” Solaru, ” Ryan, Scott Kahan, Kahan, Solaru, Christine Gallagher, Wegovy, Rebekah Carl, Carl, Jen Wexler, gaunt, Wexler Organizations: Novo Nordisk, Dartmouth, Nutrition Institute, Massachusetts General Hospital, Harvard Medical School, Reuters, Cambridge, Obesity Society, U.S ., Management, Reuters . Pharmaceutical, ”, U.S, United, National Health Service, University of California, U.S . Food, Drug Administration, Doctors, Wegovy’s, BMI, Yale University’s Center, Weight Management, Wall Street, American Medical Association, Rutgers University’s School of Public Health, Affordable, . Pharmaceutical, Companies, Uniformed Services University of Health Sciences, Wake Forest University, Wake Forest Baptist Health Weight Management, Obesity, Pennington Biomedical Research, U.S . National Institutes of Health, Personnel Management, Coalition, STOP, George Washington University, Novo Locations: CAMBRIDGE, Massachusetts, Boston, U.S, Novo, Danish, United States, Louisiana, San Francisco, Wegovy, Pennington, Baton Rouge , Louisiana, Government, New Columbia , Pennsylvania, Florida

Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. But Novo and Pfizer are also trying to develop pill versions that would be easier for patients to take. Pfizer said it saw patient discontinuation rates topping 50% across all doses in a mid-stage study of twice-daily danuglipron. It ranged from nearly 7% to more than 11% in patients taking the pills. By comparison, obese patients without diabetes lost about 18% of their weight compared to a placebo when taking taking Eli Lilly’s Zepbound in late-stage research.

Persons: Eli Lilly, Eli Lilly’s Zepbound, Mikael Dolsten Organizations: Pfizer, Novo Nordisk, Novo, Drug Administration, Pfizer Inc Locations: York

☆ Pfizer drops plan to study twice-daily obesity pill in late-stage studies
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +2 min

A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. Pfizer said it would instead focus on a once-daily, modified release version of danuglipron and "gathering the data to understand its potential profile". In the current study of the twice-daily version, Pfizer said the drug, however, met the main goal of reducing weight in adults with obesity and without type 2 diabetes. Pfizer said while the common side effects in the twice-daily version study were mild, it saw high rates of those events in the trial. However, no new safety signals were observed in the study, Pfizer said.

Persons: Carlo Allegri, danuglipron, Eli Lilly's, Mikael Dolsten, Pfizer, Manas Mishra, Michael Erman, Shinjini Organizations: Pfizer, REUTERS, Zepbound, Thomson Locations: Manhattan, New York City , New York, U.S, Bengaluru, New York

☆ We're updating price targets for 6 stocks and changing our rating for Palo Alto
▼ + stars: | 2023-12-01 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

The Club on Friday is changing the rating and price target on one of our favorite stocks, and updating the price targets on 5 other names in the portfolio to reflect recent quarterly earnings reports, new developments at the companies and broader economic forces. We're increasing our price target on shares of Palo Alto (PANW) to $300 from $280. We're raising our price target on shares of Salesforce (CRM) to $275 from $240. We're lowering our price target for Ford (F) stock to $13 from $16. We're lifting our price target on shares of Eli Lilly (LLY) to $630 from $600.

Persons: PANW, Ford, Linde's, Linde, Eli Lilly, it's, It's, Jim Cramer's, Jim Cramer, Jim Organizations: Palo, Palo Alto Networks, Costco, Ford, UAW, Management, Motors, GM, Linde, LIN, P Healthcare, donanemab, Novo Nordisk, Pfizer, CNBC Locations: Alzheimer's, Lilly, Santa Clara , California

☆ Why investors should stick with Eli Lilly
▼ + stars: | 2023-12-01 | by ( Jeff Marks | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a Morning Meeting livestream at 10:20 a.m. The treatment — which Jim Cramer has said could become the greatest-selling drug of all time — received approval from the U.S. Food and Drug Administration last month, bolstering Eli Lilly shares. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Bond, Jerome Powell, Goldman Sachs, STZ, Eli Lilly, —, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Treasury, Federal, Club, Constellation Brands, Pfizer, U.S . Food, Drug Administration Locations: U.S

☆ Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
▼ + stars: | 2023-12-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The company is betting on a successful weight loss pill to help it rebound from plummeting demand for its Covid products and a roughly 40% share price drop this year. Pfizer's phase two trial on its twice-daily pill followed around 600 obese adults who did not have Type 2 diabetes. Meanwhile, placebo-adjusted weight loss was 8% to 13% at 32 weeks and 5% to 9.5% at 26 weeks, Pfizer said. No new safety issues were observed, and danuglipron was not associated with increased liver enzymes like Pfizer's other discontinued weight loss pill.

Persons: Albert Bourla, Eli Lilly, danuglipron Organizations: Pfizer, Novo Nordisk, Nordisk's Wegovy

☆ US FDA gives second approval to Eli Lilly's drug for type of blood cancer
▼ + stars: | 2023-12-01 | by ( ) www.reuters.com time to read: +1 min

Dec 1 (Reuters) - Eli Lilly (LLY.N) said on Friday the U.S. Food and Drug Administration (FDA) gave a second approval for its drug Jaypirca, which is used to treat a form of blood cancer. The company said the health regulator gave the new approval to the drug for the treatment of chronic lymphocytic leukemia (CLL), a type of cancer in which the bone marrow makes too many of certain white blood cells. Jaypirca was first given accelerated approval by the FDA on Jan. 27 for the treatment of mantle cell lymphoma (MCL), a rare type of blood cancer that starts in white blood cells and spreads to other parts of the body. MCL is a more aggressive form of cancer compared to CLL, according to the National Institutes of Health. The drug aims to treat adults with CLL after at least two lines of therapy.

Persons: Eli Lilly, LLY.N, Jaypirca, Christy Santhosh, Arun Koyyur Organizations: U.S . Food, Drug Administration, FDA, National Institutes of Health, CLL, Thomson Locations: Bengaluru

☆ US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
▼ + stars: | 2023-12-01 | by ( Patrick Wingrove | ) www.reuters.com time to read: +5 min

REUTERS/Mike Segar Acquire Licensing RightsDec 1 (Reuters) - Some leading U.S. obesity specialists say they expect Eli Lilly’s (LLY.N) powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s (NOVOb.CO) popular Wegovy as they belong to the same class of medicines. In Novo's pivotal Wegovy trial involving 17,604 overweight and obese people without diabetes, the drug reduced incidence of heart attack, stroke or heart-related death by an impressive 20%. The product, which has the same active ingredient - tirzepatide - as its previously approved diabetes drug Mounjaro, is expected to start shipping it before the end of the year. They said they would readily prescribe Wegovy (semaglutide) if their patients' insurance did not cover Lilly’s drug, or if future trial results do not produce similar heart benefits. Lilly declined to comment on doctors' views that Zepbound might have the same or similar cardiovascular benefits as Wegovy.

Persons: Eli Lilly, Mike Segar, Eli Lilly’s, Lilly, Danish drugmaker, Edmond Wickham, Emily, Zepbound, Tirzepatide, ”, Rohit Kedia, Novo, Chad Weldy, semaglutide, tirzepatide, Farxiga, Boehringer Ingelheim, Lilly’s Jardiance, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: Company, REUTERS, Novo, Wegovy, Virginia Commonwealth University . The, Virginia Commonwealth University . The U.S . Food, Drug Administration, Wall Street, Barclays, Providence, Stanford University, Thomson Locations: Branchburg , New Jersey, Danish, Virginia Commonwealth University . The U.S, Zepbound, U.S

More than 8,000 people, mostly Native Hawaiians, perished at Kalaupapa, including Damien, who eventually contracted leprosy, later called Hansen’s disease. Damien’s love for Kalaupapa’s people was unconditional, said Barbara Jean Wajda of the Sisters of St. Francis of the Neumann Communities. “They keep me like this, make me strong.”She enjoys when people visit and when the church brings pilgrims, she said. The walls of the sisters' house, Kalaupapa’s largest dwelling, are filled with photos of the sisters who worked on the settlement after Marianne. “And we both feel connected to the patients, to the land, to the saints who were here, declared and undeclared,” Wajda said.

Persons: Saint Damien of Molokai, Kalaupapa’s, Damien’s, ”, Lance Toyofuku, ” Kalaupapa, Father Damien, Mother Marianne —, Alicia Damien Lau, Damien, Joseph De Veuster, Saint Marianne, Patrick Killilea, “ Fr, Paddy, “ It’s, Philomena, Barbara Jean Wajda, Francis, Lau, ” Marianne Cope, Marianne, Tonata Lolesio, ” Lolesio, “, Honolulu Bishop Larry Silva’s, Silva, didn’t, that’s, Wajda, Francis Church, she’s, Watanuki, ” Bishop Silva, ” Keani Rawlins, Fernandez, Mother Marianne, Marianne . Lau, Alicia, ” Wajda, ” They’ve Organizations: Toyota, National Park Service, St, Neumann, Sacred Hearts School, Honolulu Bishop, “, Associated Press, Maui County Council, Lilly Endowment Inc, AP Locations: KALAUPAPA, Hawaii, Kalaupapa, Molokai, Belgian, Hawaii’s, Honolulu, Belgium, Germany, Maui, Lahaina, American Samoa, Maui County

☆ One ETF that focuses on employee happiness is outperforming the market this year
▼ + stars: | 2023-12-01 | by ( Alex Harring | ) www.cnbc.com time to read: +6 min

Executives don't need to worry about Irrational misrepresenting their company, and participation can open them up to potential inclusion in products such as an ETF, van Adelsberg said. In total, the ETF recently held nearly 150 equities and is benchmarked to the CIBC Human Capital Index. Still, the team noted some challenges in building broader awareness of what human capital is or why it matters. "In this market, what we're seeing is that those companies who have strong human capital ratings are outperforming," van Adelsberg said. "The role that human capital plays in driving future equity performance isn't going down.

Persons: doesn't, Kristof Gleich, –, it's, Gleich, …, Morningstar, HAPI, David van Adelsberg, van Adelsberg, Eli Lilly, Johnson, Berkshire Hathaway, JPMorgan Chase, they've, It's Organizations: Capital Factor, Capital Advisors, Irrational, ETF, Microsoft, Apple, Nvidia, Meta, Morningstar, Mastercard, Berkshire, CIBC Human, JPMorgan, Securities, Exchange

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

☆ Here are Thursday's biggest analyst calls: Nvidia, Apple, Eli Lilly, Salesforce, Snowflake, Snap, Pinterest and more
▼ + stars: | 2023-11-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Jefferies upgrades Pinterest and Snap to buy from hold Jefferies sees growth upside in 2024 for both stocks. " Wolfe upgrades Ally Financial to outperform from peer perform Wolfe said in its upgrade of the financial company that it's well-positioned. "In an environment where the probability of a mild recession or soft landing both appear plausible, we believe ALLY is well positioned to outperform in either scenario and upgrade shares to Outperform." "We continue to believe that Salesforce is on track to become the next quality [growth at a reasonable price] stock." Goldman Sachs reiterates Snowflake as buy Goldman Sachs stood by its buy rating on Snowflake after earnings on Wednesday.

Persons: Berenberg, Eli Lilly, Lilly, Wells, BTIG, Jefferies, Bernstein, Burger, Wolfe, TD Cowen downgrades Okta, Cowen, Stifel, Raymond James, Morgan Stanley, Bilibili, BILI, Baird, Pat Shanahan, Wells Fargo, Salesforce, Goldman Sachs, Snowflake, DUK Organizations: pharma, Nvidia, NVIDIA, Jefferies, SNAP, BK, UBS, Service Corporation, Deutsche Bank, Lattice Semiconductor, Apple, JPMorgan, Nokia, Infineon, Watch, Hewlett Packard Enterprise, Barclays, GE Healthcare, Airbus, Bank of America, Duke Energy, HSBC, Molson Coors Locations: FTCH, North America, China

☆ Jim Cramer explains why it's hard to be bullish on the healthcare sector
▼ + stars: | 2023-11-30 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Thursday told investors why it's hard to be bullish about healthcare stocks, citing challenges stemming from government action and lack of innovation. According to Cramer, the healthcare sector is "in the crosshairs" of the U.S. government because of the upcoming election. Johnson & Johnson and Bristol Meyers are among several drug makers to file lawsuits against the government, broadly arguing that the pricing measures are unconstitutional. The Federal Trade Commission is doing its best to block mergers in the sector, Cramer said. Aside form drug makers, Cramer added that medical device companies haven't seen their business pick up since Covid, also hurting the sector overall.

Persons: CNBC's Jim Cramer, Cramer, Johnson, Bristol Meyers, Eli Lilly Organizations: Biden Administration, Johnson, Federal Trade Commission Locations: Cigna

☆ Panama trade minister resigns after mining contract backlash
▼ + stars: | 2023-11-30 | by ( Elida Moreno | ) www.reuters.com time to read: +1 min

PANAMA CITY, Nov 30 (Reuters) - Panama's Trade Minister Federico Alfaro announced his resignation on Thursday days after the country's top court ruled a contract between the government and Canadian miner First Quantum < FM.TO> was unconstitutional. The Central American country's trade ministry led negotiations on a contract between the government and First Quantum to operate a key copper mine, which opponents have deemed as too generous to the miner. In a resignation letter addressed to the president and shared on social media, Alfaro mentioned the contract, which generated months of protest throughout Panama, as well as the court ruling. Cortizo announced on Tuesday he will follow through with First Quantum's mine shutdown once the court's ruling is published in the country's official gazette, which has not yet happened. Incoming trade minister Rivera said in a separate public statement the ministry is evaluating actions to comply with the court's ruling and will start coordination talks with labor and environmental authorities.

Persons: Federico Alfaro, Alfaro, Laurentino Cortizo, Jorge Rivera, Cortizo, Rivera, Eli Moreno, Brendan O'Boyle, Isabel Woodford Organizations: PANAMA CITY, Panama's Trade, Central American, Thomson Locations: PANAMA, Panama, Lincoln

☆ Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Compounding pharmacies prepare custom-made versions of commercially available treatments to meet the specific needs of a patient. Novo Nordisk first sued Brooksville Pharmaceuticals over copycat versions of Wegovy and Ozempic in July. Including the newest lawsuits, Novo Nordisk has filed 12 legal actions against compounding pharmacies, medical spas and weight loss clinics allegedly selling dupes of Wegovy and Ozempic. That puts patients "at risk of taking drug products that are less effective than expected based on their labeling," according to Novo Nordisk. Several states have also threatened to take legal action against compounding pharmacies that make or distribute unapproved variations of Novo Nordisk's weight loss treatments.

Persons: Eli Lilly, Jason Brett, Novo Organizations: Novo Nordisk, Wells Pharmacy Network, Brooksville Pharmaceuticals, Nordisk, Wells Pharmacy, Novo, U.S . Food, Drug Administration, FDA, CNBC PRO Locations: Oslo, Norway, Florida, U.S, Danish, Ozempic

☆ Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
▼ + stars: | 2023-11-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

[1/2] Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. The Danish drugmaker said it found impurities in all the drugs tested from Wells Pharmacy and Brooksville Pharmaceuticals, both based in Florida. Novo said the compounded versions of Wegovy tested from Brooksville were also less potent than advertised, with one sample shown to be at least 19% weaker than indicated. The drugmaker has already filed 12 lawsuits against medical spas, weight-loss clinics and compounding pharmacies offering products that claim to contain semaglutide. The case against Wells was filed in the U.S. District Court, Middle District of Florida, Ocala division and the suit against Brooksville in U.S. District Court, Middle District of Florida, Tampa division.

Persons: Victoria Klesty, Danish drugmaker, Novo, Brooksville, ” Jason Brett, Eli Lilly, Mounjaro, Wells, Patrick Wingrove, Josephine Mason, Bill Berkrot, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wells Pharmacy, Brooksville Pharmaceuticals, U.S . Food, Drug Administration, FDA, Novo's, Middle District of, Brooksville, Thomson Locations: Oslo, Norway, Victoria, Danish, Florida, Wells, U.S, Middle District, Middle District of Florida, Ocala, Tampa

Hamas freed two Israeli hostages Thursday afternoon and they were brought back into Israel, with more expected to follow, the Israeli military said. Israel had agreed to extend the truce by one day for every 10 militant-held hostages who are freed. Roughly 240 hostages were captured by Hamas in its Oct. 7 attack in southern Israel that ignited the war. ISRAEL SAYS 2 MORE HOSTAGES RELEASED FROM GAZAJERUSALEM — The Israeli military said Thursday that two Israeli hostages were released from captivity in the Gaza Strip. The two hostages are among a larger group of Israelis expected to be released Thursday as part of the latest extension of a cease-fire between Israel and Hamas.

Persons: Israel, — Jake Sullivan, — Israel, Schumer, Pedro Sánchez, Eli Cohen, Sánchez “, ” Cohen, “, Sánchez, ” Sánchez, Israel ´, Karim Khan, Israel “, Khan, ISRAEL, BLINKEN, Antony Blinken, Blinken, Benjamin Netanyahu, Netanyahu, Biden, Blinken “, Mahmoud Abbas, Tzarfati, Israel —, ”, David Adom, Zaki Heller, Doron Turgeman, AHED TAMIMI Organizations: Qatar, Health Ministry, Islamic, U.S, MADRID —, Spanish, Spanish National Television, “, Belgian, ICC, Cross, HAMAS TEL, Israel — U.S, State Department, West Bank, MAN, Jerusalem police, Army, JERUSALEM, Qatari Foreign Ministry, Hamas Locations: Israel, Gaza, —, israel, MADRID — Israel, Spain, Palestinian, Egypt, Belgian, Spanish, HAGUE, Netherlands, Ramallah, GAZA JERUSALEM, ISRAEL, HAMAS TEL AVIV, U.S, Jerusalem, JERUSALEM, TEL AVIV, Qatar, AHED TAMIMI Israel

☆ Can a Big Pharma Ever Be Worth $1 Trillion?
▼ + stars: | 2023-11-29 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Daniel Skovronsky, chief scientific and medical officer at Eli Lilly, pushed the company to move more quickly and focus more on science. Photo: Maddie McGarvey for The Wall Street JournalThere are five tech companies valued at over $1 trillion. In healthcare, the closest contender is Eli Lilly . This year it became the first big pharmaceutical to surpass a market capitalization of $500 billion thanks to the popularity of its obesity and diabetes medications and, to a lesser extent, its experimental Alzheimer’s drug. But hanging over Lilly and rival Novo Nordisk is a reality that puts the brakes on big pharma’s ascent: the patent cliff.

Persons: Daniel Skovronsky, Eli Lilly, Maddie McGarvey, Lilly Organizations: Wall, Novo Nordisk

☆ Jim Cramer looks at why Eli Lilly is the 'only drug stock that’s working' right now
▼ + stars: | 2023-11-29 | by ( Paulina Likos | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer releases the Homestretch audio feature in time for the last hour of trading on Wall Street. Elsewhere, Jim Cramer called biopharma stock Eli Lilly (LLY) "the only drug stock that's working" in a competitive health care field. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Stocks, Locker, Mary Dillon's, Eli Lilly, Lilly, bode, Jim, FTC's Lina Khan, Jim Cramer's Organizations: CNBC, Meta, Club, UnitedHealth, FTC, Jim Cramer's Charitable

☆ GLP-1 weight loss drug boom to boost energy drink stocks, Lululemon, Stifel says
▼ + stars: | 2023-11-29 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Further uptake of the blockbuster weight loss drugs rocking the health-care world can bode well for select energy drink makers and fitness-focused retailers, Stifel said. Indeed, Stifel found an additional 21% said they would be interested in the drug if it showed proven results, was widely available and had approval from the U.S. Food and Drug Administration for weight loss specifically. Wegovy was approved to treat weight loss in 2022 and Eli Lilly's Zepbound recently received that same nod . These shifting food and health habits can also affect consumer spending — and stocks tied to specific retailers, Astrachan said. If half of those interested in GLP-1 drugs begin taking them, the firm expects U.S. energy drink consumption could increase about 2%.

Persons: bode, Stifel, Wegovy, Eli Lilly's Zepbound, Mark Astrachan, Astrachan, Atkins, Levi Strauss, Lululemon, — CNBC's Michael Bloom Organizations: Nordisk's Ozempic, U.S . Food, Drug Administration, Monster Beverage, Holdings, Food, BellRing Brands, Brands Locations: Stifel's U.S, U.S

Donations were up $20 million on Tuesday, a 0.6% increase over last year before adjusting for inflation, the nonprofit said. GivingTuesday makes its estimate by drawing on data from donor management software companies, donation platforms, payment processors and donor-advised funds. Political Cartoons View All 1273 ImagesIt's still too early to know whether end-of-year giving will pull charitable donations back up this year. “We absolutely lean into those traditional cycles of giving, which I feel like GivingTuesday really capitalizes on,” she said. GivingTuesday's estimates don't include gifts to mutual aid groups, donations to political organizations or gifts made directly to individuals, Rosenbaum said.

Persons: GivingTuesday, ”, Woodrow Rosenbaum, Rosenbaum, Elaine Kenig, “, Kenig, Naomi Thompson, ” Rosenbaum Organizations: —, “, ” Nonprofit, Vanguard Charitable, Lilly Endowment Inc, AP Locations: U.S, Maui, Northern Ireland

☆ Thailand welcomes release of two more Thai hostages held by Hamas
▼ + stars: | 2023-11-29 | by ( ) www.reuters.com time to read: +2 min

"Happy to personally welcome 2 additional Thai hostages just released and arrived at the hospital in Tel Aviv," Parnpree, who is also deputy prime minister, posted on social media platform X. Nineteen Thai hostages have so far been released, while the foreign ministry says 13 more remain in captivity. A Thai Muslim group that spoke directly with Hamas said on Monday its efforts were key to ensuring Thai hostages were among the first to be released. A Thai foreign ministry spokesperson said multiple actors were consulted. The Thai citizens released are slated to return home this week as Parnpree visits Israel.

Persons: Parnpree Bahiddha, Eli Cohen, Uriel Bosso, Nukara, Parnpree, Orathai Sriring, Panarat, Tom Hogue, Martin Petty Organizations: Thai Foreign, Israeli, Hamas, Thomson Locations: Gaza, BANGKOK, Israel, Tel Aviv

Search resuls for: "Eli Lilly

25 mentions found